Stanford’s AI-Designed Phages: Why This Matters Researchers at Stanford University and the Arc Institute used Evo 2 (a generative AI model for DNA design) to create complete bacteriophage genomes. Starting from ΦX174, they synthesised nearly […]
Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the […]
Across women’s health, there is growing recognition of the urgent need for antibiotic‑sparing strategies that restore and sustain an optimal vaginal microbiota. Such an ecosystem is typically dominated by Lactobacillus crispatus, a species strongly associated […]
A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women […]
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by […]
In the past 10 years, there has been significant interest in new classes of active pharmaceutical ingredients (APIs). These novel APIs include live biotherapeutics, which are used for microbiome targeting drugs, oral biologics like GLP1 […]
With Expert’Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and […]